HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Insight’s Key Takeaways From 2021: #3 Keep Your Eye On AI

Executive Summary

The future of digital health will be shaped more than anything else by the rise of artificial intelligence. From body enhancing bio-wearables to camera-based skin diagnostics, the consumer health industry continued to explore the possibilities presented by AI in 2021. However, there are many regulatory and ethical hurdles industry must overcome as we move into 2022 and beyond.

You may also be interested in...



UK Recommends Digital Therapy App For Insomnia Sufferers

Big Health’s Sleepio app – which delivers cognitive behavioral therapy for insomnia – has been endorsed as an effective alternative to sleeping pills by the UK's National Institute for Health and Care Excellence.

More Big Beauty Companies Partner With Digital Tech To Guide Consumer Journey

Beiersdorf AG and dermanostic will connect German consumers with physicians for mobile app-based dermatological diagnoses and product recommendations. Meanwhile, Shiseido will be leveraging Revieve’s AI Makeup Advisor to “take control over the multi-touchpoint customer journey.”

Abbott Expands Lingo Bio-wearables Line From Measuring Glucose To Ketone, Lactate, Alcohol

Abbott announced at CES 2022 it is developing a line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year. 

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel